Abstract 159P
Background
Malignant melanoma (MM) accounts for 80% of skin cancer-related deaths despite representing only 4% of cases. Immunotherapy has achieved promising results regarding recurrence-free survival (RFS) and overall survival (OS) in patients with MM. Thus, dendritic cell vaccination (DCvax) represents an anti-tumor autologous cell therapy with an excellent toxicity profile.
Methods
We designed a phase II trial to provide an autologous tumor lysate-loaded DCvax combined with immunomodulating radiotherapy (RT) and/or pre-leukapheresis IFN-α in patients (pts) with unresectable stage III or stage IV MM. Pts were randomised in 4 ARMS (Arm A: DCvax +RT; Arm B: DCvax + IFN-α; Arm C: DCvax +RT +IFN-α; Arm D: DCvax) to: a) determine the safety of the DCvax in combination with IFN-α and/or RT; b) select the regimen with the highest immune-related Disease Control Rate (irDCR) used in combination with DCvax; c) compare immunologic efficacy between the different treatment arms, defined as the proportion of subjects developing positive DTH to the Autologus Tumor Lysate (ATL) and/or KLH, along with tumour antigen-specific circulating immune effectors quantification at the baseline and after at least 4 DCvax doses. Furthermore, an in-depth study of DC recovery, functionality, and a full characterization of pt’s circulating immune profile was conducted. The findings were correlated with pt’s clinical outcome.
Results
Overall, 34 pts were enrolled from 2013 to the end of 2022, of whom only 29 were evaluable and fairly balanced for sex. Arm A pts (n=7): median age 65.8 years (yrs), OS 5.3 months (mos) (95% CI: 2.5-NR); arm B (n=8): age 54.8 yrs, OS 11.2 mos (1.2-NR); arm C (n=7): age 69.6 yrs, OS 8 mos (2-NR); arm D (n=7): age 66.9 yrs, OS 20.7 mos (11.7-NR). Notably, pts treated with the vaccine alone or with IFN-α pre-leukapheresis exhibited a positive DTH test in 83% and 71% of cases, respectively. Furthermore, the immune-related response to therapy observed in our cohort showed a higher irDCR in arm D (DCvax only) at 57% (p = 0.099).
Conclusions
We demonstrate the safety profile of DCvax in advanced MM pts and highlight unique immunomodulatory traits, paving the way for new therapeutic approaches combining immunotherapy and autologous cell therapies.
Clinical trial identification
EudraCT 2012-001410-41.
Legal entity responsible for the study
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy.
Funding
This work was partly supported thanks to the contribution of 5x1000 by the Italian Ministry of Health.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
205P - Advancing pre-clinical functional tests with immune-responsive Precision Cut Bladder Tumor Slices (PCTS)
Presenter: Sarah Richtmann
Session: Poster Display session
Resources:
Abstract
206P - Characterisation of tumour-infiltrating lymphocytes (TILs) in liver metastases (LM) and primary tumour (PT) of microsatellite stable (MSS) colorectal cancers
Presenter: Yi Hua Low
Session: Poster Display session
Resources:
Abstract
207P - ZEB2 inhibition relieves TAMs-mediated immunosuppression in EGFR-TKI resistant NSCLC
Presenter: Yunhuan Liu
Session: Poster Display session
Resources:
Abstract
208P - Targeting pro-tumor TAMs to improve immune checkpoint response of advanced bladder cancer
Presenter: Marine Leblond
Session: Poster Display session
Resources:
Abstract
209P - Mapping the landscape of immune cells for optimal index calculation using AI-powered image analysis of multiplexed immunohistochemistry in breast cancer patients
Presenter: Patricia Nielsen
Session: Poster Display session
Resources:
Abstract
210P - Precision immuno-oncology strategies to overcome drug resistance in non-small cell lung cancer
Presenter: Heidi Haikala
Session: Poster Display session
Resources:
Abstract
211P - Single-cell characterization of differentiation trajectories and drug resistance features in gastric cancer with peritoneal metastasis
Presenter: Haoxin Peng
Session: Poster Display session
Resources:
Abstract
212P - YAP/TEAD4/SP1-induced VISTA expression as a tumor cell-intrinsic mechanism of immunosuppression in colorectal cancer
Presenter: Zhehui Zhu
Session: Poster Display session
Resources:
Abstract
214P - DNA-damaging therapies trigger transcriptome and metabolism changes in peripheral NK cells of SCLC patients
Presenter: Caterina de Rosa
Session: Poster Display session
Resources:
Abstract
215P - Differential spatial gene expression and clinicopathologic characteristics are associated with exceptional response to immune checkpoint inhibition in recurrent/metastatic head and neck cancer
Presenter: Niki Gavrielatou
Session: Poster Display session
Resources:
Abstract